GLG News by Lexapro Prescribers: Psychiatrists (US)

Sosei Group Corporation (a Japanese Biopharm Co.) is targeting Fibromyalgia with AD 337.  Does a disappointing Phase II proof of principle bode poorly for this drug?

Shire (SHPGY) has run into some difficulties with the Daytrana patch, related to problems with liner removal, leading to voluntary withdrawal of some product.  Is this a minor blip or will it undermine confidence in the product by patients/physicians?

Actelion is one of the companies pursuing a promising first-in-class potential blockbuster for the sleep market.  But its ultimate success with almorexin hinges on several factors.

A study of late stage Alzheimer's Disease patients shows some improvement in cognitive function with Donepezil...the significance of this is questionable...and the market effect probably minimal considering several factors.

Sanofi after facing defeat with the FDA hopes to prove with further clinical trials the satety and effectivenss of Accomplia...If successful, this might be huge.

1. Shire has withdrawn patches that had defective patch liners. 2. This defect is not related to safety or efficacy issues. 3. The cost to Shire is less than $10 million.

1. Lu AA21004 and Lu AA24530 are two compounds with a great deal of potential and will be co-marketed jointly by Takeda and Lundbeck. 2. Lu AA21004 is the more advanced of the compounds and is currently in phase II development for the treatment of major depression. 3. The compounds potentially address...

1. LY2140023 is an antipsychotic agent that is a metabotropic glutamate 2/3 receptor agonist. This agent has a new mechanism of action that is efficacious in treating schizophrenia and potentially other neuropsychiatric conditions. 2. LY2140023 in addition to separating from placebo in a statistically...

1. The Actelion agent (ACT-078573) is not a sedative-hypnotic but is an orexin receptor antagonist. 2. This agent may have a safety and tolerability profile that is better than the sedative-hypnotics. 3. The above implications would make Actelion a prime acquisition for a big-pharma company with a less...

1. A recent psychiatric journal reported a higher incidence of bipolar disorders in the pediatric population and a subsequent increase in antipsychotic medication use in children. 2. Assessment tools (bipolar disorder questionnaires) have significantly increased awareness of bipolar disorder symptomatology...